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A B S T R A C T
A-type resistance towards “last-line” glycopeptide antibiotic vancomycin in the leading hospital acquired
infectious agent, the enterococci, is the most common in the UK. Resistance is regulated by the VanRASA two-
component system, comprising the histidine sensor kinase VanSA and the partner response regulator VanRA. The
nature of the activating ligand for VanSA has not been identiﬁed, therefore this work sought to identify and
characterise ligand(s) for VanSA. In vitro approaches were used to screen the structural and activity eﬀects of a
range of potential ligands with puriﬁed VanSA protein. Of the screened ligands (glycopeptide antibiotics
vancomycin and teicoplanin, and peptidoglycan components N-acetylmuramic acid, D-Ala-D-Ala and Ala-D-y-
Glu-Lys-D-Ala-D-Ala) only glycopeptide antibiotics vancomycin and teicoplanin were found to bind VanSA with
diﬀerent aﬃnities (vancomycin 70 μM; teicoplanin 30 and 170 μM), and were proposed to bind via exposed
aromatic residues tryptophan and tyrosine. Furthermore, binding of the antibiotics induced quicker, longer-lived
phosphorylation states for VanSA, proposing them as activators of type A vancomycin resistance in the
enterococci.
1. Introduction
Vancomycin is a tricyclic glycopeptide (molecular weight = 1449)
which is used as a ﬁrst-line treatment for complicated diseases including
skin and blood infections, endocarditis, bone and joint infections and
meningitis in addition to infections caused by methicillin-resistant
Staphylococcus aureus [1]. Vancomycin and related glycopeptide antibiotics
(GPAs) target transpeptidase and transglycosylase activities by binding to
the C-terminal D-Ala-D-Ala dipeptide of the muramyl pentapeptide of
peptidoglycan precursor Lipid II which inhibit the ﬁnal steps of bacterial
cell wall biosynthesis. High aﬃnity hydrogen bonds are formed between
vancomycin and peptidoglycan precursors [2–4], sequestering the peptido-
glycan precursors and physically inhibiting transpeptidase and transglyco-
sylase cross-linking for the formation of mature peptidoglycan cell walls
[4–9]. Crosslinking of the growing peptidoglycan, formation of glycan
chains and incorporation of peptidoglycan precursors is prevented leading
to osmotic shock and cell lysis [6,7,9].
Using model cell wall precursor peptides such as N-acetyl-D-Ala-D-
Ala, binding studies in aqueous solution have established that for many
glycopeptides, the formation of entropically favourable asymmetric,
back-to-back homodimers of the antibiotic [10–12] is mediated by
sugar-sugar recognition [12,13]. Although vancomycin dimerisation is
generally considered to be in a back-to-back conﬁguration, crystal
structural information of vancomycin in complex with N-acetyl-D-
alanine revealed the existence of both back-to-back and face-to-face
dimers, though the relative importance of each these conﬁgurations in
antimicrobial action and aﬃnity remains to be established [14].
Dimerisation is suggested to enhance the activity of the antibiotic,
and this is supported by in vitro studies showing dimerisation and
binding of D-Ala–D-Ala are generally cooperative phenomena [15]. It
has been proposed that the dimer binds two adjacent cell wall
precursors and that binding to D-Ala–D-Ala at one site on the
glycopeptide dimer anchors the dimer to the cell wall and thereby
enhances the second binding event through the chelate eﬀect resulting
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in a stabilised complex [15]. Molecular dynamic simulations and free
energy calculations agree, favouring peptidoglycan-glycopeptide inter-
actions rather than direct membrane binding of glycopeptides [16].
Surface plasmon resonance and other studies revealed a kd value for
vancomycin binding of 1.32 μM [17], 2.7 μM [18] and 3.39 μM [19],
indicative of moderate binding. In the case of the lipophilic glycopep-
tides such as teicoplanin which do not dimerise but do target the C-
terminal D-Ala-D-Ala dipeptide of peptidoglycan [20,21] with greater
potency than vancomycin demonstrated in vitro and in vivo [22–24],
anchorage into the membrane occurs via the lipid moiety and this
anchorage positions the antibiotic at its site of action at the cell surface
resulting in an increased eﬀectiveness of the antibiotic [25,26].
GPAs are considered “last-line” treatments against multi-resistant
organisms (MROs). Wide-spread use during the 1970s towards MROs
and Gram-positive organisms including enterococci which have innate
resistance towards some antibiotics including β-lactams, e.g. penicillin
[27–30] has been attributed a main factor for the development of
vancomycin resistant enterococci (VRE) [31,32]. Resistance to the
glycopeptide antibiotics amongst clinical bacteria has emerged and
spread across the world at a rapid rate [33].
Of the 6 types of vancomycin resistance [5,34], type A which was ﬁrst
discovered in E. faecium strain BM4147 [34,35]. The VanA phenotype
shows the highest level of inducible resistance towards both vancomycin
and teicoplanin and is the most common in the UK [36]. Genes required for
type A vancomycin resistance are contained within the vanA operon.
Expression results in (1) synthesis of low-aﬃnity D-Ala-D-Lac for dipeptide
incorporation, and (2) removal of high-aﬃnity D-Ala-D-Ala from early and
late peptidoglycan precursors resulting in and overhaul of the incorporated
peptidoglycan to D-Ala-D-Lac [5,27,37]. The alternative peptidoglycan
precursor lacks a key hydrogen bond site normally exhibited by the D-
Ala-D-Ala dipeptide, resulting in a 1000-fold reduced aﬃnity for vancomy-
cin [38]. This allows the cell to produce mature cross-linked peptidoglycan
and to bypass the cytotoxic activities of vancomycin [5,39,40].
Furthermore, concerns for the inter- and intra-species spreading of
resistance genes due to the encoding of resistance genes on mobile
genetic elements [29] increased after the ﬁrst in vitro transfer of type A
vancomycin resistance genes from enterococci to staphylococci [32],
later conﬁrmed in vivo [41–43].
Expression of the vanA operon is controlled by the two-component
signal transduction system VanRASA [44], comprised of the signal
sensing membrane sensor histidine kinase VanSA and partner response
regulator VanRA which is responsible for activating resistance gene
expression [5]. Autophophorylation of the cytosolic kinase portion of
VanSA and phosphotransfer to VanRA has been demonstrated in vitro
[45]. VanR ~ P has been demonstrated to have increased aﬃnity for
van promoters than VanRA [46]. The presence of VanRA ~ P increases
transcription of (1) the PvanR promoter regulating VanS/VanR expres-
sion therefore regulates its own synthesis, and (2) the PvanH promoter
for the vanHAAAXA resistance operon expression [47]. The vanA operon
is constitutively expressed in the absence of VanSA as a result of the
production of VanRA ~ P generated from acetyl phosphate and/or
cross-talking histidine kinase phosphodonors [47]. Overall, it is sug-
gested that in the absence of inducer, VanSA phosphatase activity
negatively regulates VanRA by dephosphorylating VanRA through its
phosphatase activity preventing any signiﬁcant resistance gene expres-
sion. In the presence of inducer, VanSA switches from phosphatase to
kinase mode, resulting in higher levels of VanRA ~ P and resistance
gene expression [48] [47].
The nature of the activating inducer for VanA-type resistance
remains unknown. Vancomycin has been suggested as a ligand for type
A systems [49,50] and has recently been shown to bind in type A
equivalent systems of actinomycetes [51]. Other proposed ligands
include the antibiotic-peptidoglycan precursor complex [52] and the
accumulating peptidoglycan precursors as a result of vancomycin mode
of action [53,54]. Here, we describe the use of in vitro approaches to
further characterise the ligand-induced activities of VanSA.
2. Materials and methods
2.1. Materials
Vancomycin, teicoplanin, N-Acetyl-D-glucosamine, N-Acetyl
muramic acid, D-Ala-D-Ala, Ala-D-γ-Glu-Lys-D-Ala-D-Ala all purchased
from Sigma-Aldrich (UK). IPTG, n-dodecyl-β-D-maltoside, carbenicillin
purchased from Melford chemicals Ltd.
2.2. Gene cloning
The vanS gene of Enterococcus faecium BM4147/pFD225 possessing
the A-type resistance to vancomycin has been described previously
[50,55-57].
2.3. Medium-scale expression and puriﬁcation of VanSA
6× 1 L of LB was inoculated with 1 ml of started culture, growing
cells in the presence of 100 μg/ml carbenicillin at 37 °C to OC600 (0.6)
before induction of VanSA expression by addition of 1 mM IPTG. After
induction for 3 h at 30 °C cells were harvested at 8000 ×g (av) for
10 min. Cells were washed in 10 mM Tris–HCl pH 8.0, 10% glycerol,
0.5 mM EDTA and centrifuged at 8000 ×g (av) before resuspending in
the same buﬀer and storage at−80 °C as described in [55,58]. Thawed
cell pellets from 6 L of culture resuspended in 10 mM Tris–HCl pH 8.0,
10% glycerol, 0.5 mM EDTA were lysed by explosive decompression
using a Benchtop cell disruptor (Constant Systems Ltd). Cell lysis was
centrifuged at 12,000 ×g (av) for 40 min at 4 °C to remove cell debris,
and the supernatant removed and ultracentrifuged at 131,000 ×g (av)
for 2 h at 4 °C. The supernatant was removed and the pellet was washed
by resuspending in 10 mM Tris–HCl pH 8.0 and 2 mM β-mercaptoetha-
nol and ultracentrifuging at 131,000 ×g (av) for 1 h at 4 °C. The was
step was repeated a further two times before a resuspending the mixed
membranes in 10 mM Tris–HCl pH 8.0 and storage at −80 °C.
Puriﬁcation was conducted as described in [55]. Mixed membrane
preparations were adjusted to 4 mg/ml for solubilisation in 10 mM
HEPES pH 8.0, 20% glycerol, 1% n-dodecyl β-D-maltoside (DDM),
20 mM imidazole pH 7.9, 2 mM β-mercaptoethanol for 4 h at 4 °C with
gentle agitation before ultracentrifugation at 131,000 ×g (av) for
40 min at 4 °C. Supernatant was incubated for 8 h with Ni-NTA Agarose
(Qiagen) pre-equilibrated with 10 mM HEPES pH 8.0, 20 mM imidazole
pH 7.9, 20% glycerol, 0.025% DDM. Recovered resin was washed with
Wash buﬀer (10 mM HEPES pH 8.0, 20 mM imidazole pH 7.9, 20%
glycerol, 0.025% DDM) through a 30 ml column before eluting with 5
column volumes of Elute buﬀer (10 mM HEPES pH 8.0, 20 mM
imidazole pH 7.9, 20% glycerol, 0.025% DDM), collecting in 1 ml
fractions. Protein-containing fractions were pooled and concentrated
to 1 ml (Vivaspin®6 (100 kD MWCO)) before dialysing (Spectra/Por®
Float-A-Lyzer® G2 (3.5–5 kDa)) into Exchange buﬀer (10 mM HEPES
pH 8.0, 20% glycerol, 0.025% DDM).
The ﬁnal protein preparation prepared by concentrating protein-
containing elute fractions to 1 ml (Vivaspin®6 (100 kD MWCO)) before
dialysing (Spectra/Por® Float-A-Lyzer® G2 (3.5–5 kDa)) into Exchange
buﬀer (10 mM HEPES pH 8.0, 20% glycerol, 0.025% DDM).
2.4. Western blotting
Western blot performed as described in [55]. Image acquisition
using a ChemiDoc™ XRS+ (BioRad), and densitometry analysis pre-
formed using ImageJ [59,60]. Western blots were performed in
Transfer buﬀer (25 mM Tris, 200 mM glycine, 20% methanol) under
standard conditions (90 V, 1 h). The protein-blotted polyvinylidene
diﬂuoride (PVDF) membrane was blocked overnight in 10% (w/v) milk
in 1× TBST (10 mM Tris–HCl pH 7.5, 100 mM NaCl, 1% (v/v) Tween
20). The membrane was probed with Anti-His6 antibody (INDIA) and
developed by incubating with SuperSignal™ West Pico Chemilumines-
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cent Substrate (Thermo Scientiﬁc) and exposing to ﬁlm. Image acquisi-
tion using a ChemiDoc™ XRS+ (BioRad), and densitometry analysis
performed using ImageJ [59,60].
2.5. Protein concentration determination using A280
Protein concentration determination was carried out using a P-class
330 nanophotometer (Implen). The Beer-Lambert law was applied
using the calculated extinction coeﬃcient (ɛ) 45,770 M−1 cm−1 for
VanSA-His6.
2.6. Synchrotron radiation circular dichroism (SRCD) and circular
dichroism (CD)
SRCD spectroscopy was carried out in a nitrogen-ﬂushed chamber at
beamline B23 at the Diamond Light Source Ltd., Oxfordshire as
described in [61,62]. For CD studies, experiments were conducted
using a Chirascan-Plus (Applied Photophysics).
Ligand-containing samples were performed by addition of 5-fold
molar equivalent of ligand stocks in 10 mM Tris–HCl pH 8.0 (control
incubated with equivalent volume of 10 mM Tris–HCl pH 8.0). All
samples were incubated at 20 °C for 30 min prior to data collection. All
data was analysed using CDApps [63] where the mean residue weight
of VanSA was taken to be 113. Unless otherwise stated, all spectra
presented are diﬀerence spectra where all relevant background buﬀers,
ligands etc. have been subtracted. Data acquired when the HT of the
detector (PMT) was equal to or> 600 V were excluded from the
analyses. Far-UV measurements (180–260 nm) were commonly col-
lected using 0.5 mg/ml of VanSA with bandwidth of 1 nm and 1 s
integration time. Data presented in molar extinction (Δε). Temperature
denaturation measurements were collected over the temperatures
(20 °C–95 °C, in 5 °C increments) in the absence and presence of
ligands. Samples were incubated at the initial 20 °C for 30 min after
ligand or solvent addition prior to data acquisition. At each temperature
step, reactions were incubated for 2 min prior to data collection (1
scan). A ﬁnal scan was acquired post-temperature ramp after returning
to 20 °C and incubation for 20 min before data acquisition. Data was
analysed using CDApps [63] to obtain diﬀerence spectra where all
controls (buﬀers, ligands, etc.) had been subtracted. Change in CD
(mdeg) at a speciﬁc wavelength was transferred to OriginPro® 9 and
plotted against the corresponding temperature for ﬁtting using Gibbs-
Helmholtz equation derived from Boltzmann distribution [64,65]
sigmoidal two-state denaturation curve to a Boltzmann distribution
and the expression modiﬁed to include parameters for ﬁtting of thermal
denaturation data for the calculation of the melting temperature (Tm).
Secondary structure estimations of VanSA were performed from data
collected in the far-UV region using the CONTINLL algorithm [66–68]
and SMP 56 (43 soluble, 13 membrane) database.
Near-UV measurements (260–350 nm) were collected using 1 mg/
ml of protein using 10 mm pathlength cell, 2 nm bandwidth, 1 nm
increments and 1 s integration. Titration experiments were conducted
as described for standard near-UV measurements, with the modiﬁcation
of measurements collected after the addition of incremental volumes of
ligand stock as described previously [69,70]. Change in CD (mdeg) a
speciﬁc wavelength was monitored, the values transferred to Origi-
nPro® and plotted against respective ligand concentration (M) and
ﬁtted with a hill1 binding [71] or biphasic dose response [72] function
to determine the kd for binding.
2.7. Magnetic synchrotron radiation circular dichroism (MSRCD)
The natural CD and SRCD of proteins in the far-UV region is
sensitive to their conformation adopted in solution as a function of
environment such as solvent polarity, temperature, surfactants, salts,
pH and ligand binding interactions. In the near UV region the CD of
Tryptophan (Trp) and Tyrosine (Tyr) aromatic amino acid residues are
sensitive to their local environment and are natural probes that can be
used to determine ligand binding interactions [73]. The MSRCD on the
other hand is far less sensitive to the protein backbone conformational
behaviour and for Trp and Tyr aromatic side-chain local environments
[74,75]. In the near UV region, the dominating MSRCD of Trp
compared to that of Tyr has been found recently to be sensitive to
ligand binding [76,77] suggesting the molecular interaction is aﬀecting
the rotation of electron charge during excitation hence the magnitude
of the MSRCD signal. MSRCD is therefore a very useful spectroscopic
technique to determine the intimate involvement of Trp and Tyr at the
ligand binding interface.
MSRCD measurements were made in the near-UV region
(260–340 nm) at 20 °C in 1 nm increments using a cell of 1 cm
pathlength, 1.2 nm bandwidth and 1 s integration time. Three scans
were acquired per sample in the presence of a magnetic ﬁeld (1.4 T,
OLIS) (North-South and South-North orientation). Measurements were
analysed using CDApps [63] ﬁrst by determining the buﬀer subtracted
spectra by subtracting appropriate buﬀers from each component, e.g.
North-South (NS) buﬀer from NS measurements; and South-North (SN)
buﬀer from (SN) measurements. Resulting SN measurements were
subtracted from NS measurements for each condition, e.g. SN VanSA
(SN buﬀer_subtracted) – NS VanSA (NS buﬀer_subtracted) using Origi-
nPro®. Analysed ligands alone were subtracted from the measured
spectra, where appropriate.
2.8. Fluorescence spectroscopy
Fluorescence spectroscopy was carried out using a Chirascan-Plus
CD Spectrometer (Applied Photophysics) using 1 cm pathlength cell
(1 cm × 1 cm, 4 mm× 4 mm window) at 23 °C, 5 nm bandwidth and
600 V, 295 nm excitation wavelength to excite the VanSA Trp residues
was applied to the sample and emission monitored between 300 and
500 nm in 1 nm increments. Samples incubated at 20 °C for 30 min
prior to data collection.
Data analysis performed using CDApps [63] to obtain values which
have been buﬀer subtracted and dilution-corrected for all components
(F values) (protein only, ligand only, protein-ligand). Fo values were
determined by normalisation to the initial value for each condition,
followed by calculation of F/Fo using OriginPro® 9. Standard deviation
(n= 3) shown by error bars.
2.9. Activity assays
Assays were conducted as per the instructions provided in the R &D
Systems Universal Kinase Activity Kit (Catalogue # EA004, R & D),
changing the pH to 8.0; therefore all assays were conducted in 25 mM
HEPES pH 8.0, 150 mM NaCl, 10 mM MgCl2, and 10 mM CaCl2.
Compatibility checks for the activity of CD39L2 were made in the
new conditions [78]. A phosphate standard curve in the new assay
conditions was used to determine the conversion factor (CF) for
CD39L2 by calculating the slope of OD620 × phosphate input
(KH2PO4). This CF was used in later calculations to determine the
amount of PO42− produced in later experiments. For ligand screens,
VanSA (0.2 μg) was incubated in the absence and presence of 5-fold
molar equivalent of ligands for 20 min prior to the initiation of
autophosphorylation by the addition of ATP; after which autopho-
sphorylation was allowed to proceed for 40 min before reactions were
stopped by the addition of 30 μl Malachite Green Reagent A (ammo-
nium molybdate in 3 M sulphuric acid) at t= 60. 100 μl distilled H2O
was added to each well, followed by 30 μl of Malachite Reagent B
(malachite green oxalate and polyvinyl alcohol) and the colour allowed
to develop for 20 min before determining the optical density at 620 nm.
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3. Results and discussion
3.1. Veriﬁcation of the successful expression and puriﬁcation of active
VanSA
Protein bands (~42 kDa) which were revealed using SDS-PAGE as
being present only under induction conditions (Fig. 1A and B) were
later conﬁrmed by Western blot as VanSA (Fig. 1A and B). VanSA was
subsequently puriﬁed successfully, its identity conﬁrmed again using
SDS-PAGE and Western blot (Fig. 1C, D) in addition to N-terminal
sequencing and LC-MS/MS mass spectrometry which conﬁrmed the
expressed protein to have the expected amino acid sequence for VanSA
(Figs. 1 and 3 [79]). The observed molecular weight for VanSA using
SDS-PAGE (~42 kDa) was supported by SEC-MALS and LC-MS/MS
mass spectrometry with output values of 41,510 ± 930 Da, and
45,764 Da, respectively (Figs. 2 and 3 [79]). Membrane proteins have
been reported to migrate anomalously using SDS-PAGE resulting in
lower-than-predicted molecular weight outputs [55,80] and this may
account for the lower reported molecular weight by SDS-PAGE and
SEC-MALS. Autophosphorylation activity screens conﬁrmed the puriﬁ-
cation of active proteins (Fig. 1E) which can be used in subsequent
ligand binding and activity screens, indicative of no deleterious eﬀect of
the presence of detergent on the activity of the protein, similar to
results previously reported [55].
Following the production of pure and active protein, biophysical
approaches including circular dichroism (CD), magnetic synchrotron
radiation circular dichroism (MSRCD) and ﬂuorescence spectroscopy in
addition to phosphorylation activity assays were employed to screen a
range of candidate compounds (GPAs vancomycin and teicoplanin, and
peptidoglycan components) for their eﬀects on VanSA structure and
activity.
3.2. Assessment of the eﬀects of ligand binding on the conformation and
stability of VanSA
Ligand binding can induce conformational changes in a protein.
Using circular dichroism (CD), changes to the secondary structure (far-
UV region, 180–260 nm) and tertiary structure (near-UV region,
aromatic region, 260–310 nm) can be monitored [81,82]. Ligand
screens conducted in the far-UV region revealed no signiﬁcant con-
formational change for VanSA in the presence of screened compounds in
agreement with previous ﬁndings [49] with no signiﬁcant change in the
secondary structure estimations (α-helix, 0.04–0.3%; β-strand
0.4–1.6%, turns 0.1–2%, unordered 0.2–0.3%, normalised mean resi-
dual standard deviation (NMRSD) is 0.06–0.12).
Diﬀerences in the thermal stability of a protein in the absence and
presence of ligands can be indicative of binding interactions, therefore
thermal denaturation experiments were conducted in the far-UV region
as a complementary method for the assessment of binding of the
proposed ligands.
A signiﬁcant increase of the thermal stability for VanSA was
observed only in the presence of vancomycin (Table 1; Figs. 5 [79])
and not in the presence of peptidoglycan components suggestive of
protein-ligand interactions between VanSA and vancomycin which are
favourable to VanSA stability.
Fig. 1. Overexpression, puriﬁcation and conﬁrmation of active VanSA. (A) Coomassie-stained SDS-PAGE gel and (B) Western Blot of mixed E. colimembranes from uninduced and induced
BL21[DE3] cells harbouring the overexpression plasmid pTTQ. (C) Coomassie-stained SDS-PAGE gel and (D) Western Blot of puriﬁed VanSA. (E) Autoradiograph of VanSA,
phosphorylation assay.
Fig. 2. Ligand binding screens of VanSA in the far-UV region (190-260 nm). Diﬀerence
spectrum of VanSA in the absence and presence of 5-fold molar equivalent of compounds
(vancomycin, teicoplanin, N-acetylmuramic acid, D-Ala-D-Ala and Ala-D-y-Glu-Lys-D-
Ala-D-Ala).
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3.3. Investigation of the role of tryptophan and tyrosine in glycopeptide
antibiotic binding by VanSA
Next, screens were conducted in the near-UV region to determine
the eﬀects of the presence of screened ligands on the local tertiary
structure of VanSA, speciﬁcally screening the aromatic residues of
VanSA. Qualitative studies revealed changes to the tyrosine/tryptophan
region only in the presence of vancomycin and teicoplanin (Fig. 3A) in
agreement with previous ﬁndings for vancomycin [49] and the ﬁrst in
vitro demonstration of binding by teicoplanin. Furthermore, results
disregarded peptidoglycan components screened as binding ligands
since no signiﬁcant changes were observed (Fig. 3A). Titration studies
Fig. 3. Characterisation of ligand binding in the near-UV region (260–230 nm). Diﬀerence spectrum of (A) VanSA in the presence of 5-fold molar equivalent of compounds (vancomycin,
teicoplanin, N-acetylmuramic acid, D-Ala-D-Ala and Ala-D-y-Glu-Lys-D-Ala-D-Ala); (B) titration of vancomycin and (C) titration of teicoplanin. Binding constant (kd) calculated from
change in CD (mdeg) at (B) 286 nm and (C) 292 nm, plotting against respective concentration (M) of GPA and ﬁtting with a (B) Hill1 or (C) BidoseResponse function. Standard deviation
(n= 4) shown by error bars.
Table 1
Melting temperature of VanSA in the presence of screened compounds monitored at
222 nm.
Melting temperature (Tm) of VanSA in the presence of screened ligands (°C)
VanSA 44 ± 0.71
VanSA + vancomycin 79 ± 4.04
VanSA + N-acetylmuramic acid 44 ± 0.63
VanSA + D-Ala-D-Ala 48 ± 4.07
VanSA + vancomycin + Ala-D-γ-Glu-Lys-D-Ala-D-Ala 44 ± 2.23
VanSA + Ala-D-γ-Glu-Lys-D-Ala-D-Ala 51 ± 3.23
VanSA + teicoplanin 47 ± 5.08
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demonstrated diﬀerences in aﬃnity for each antibiotic. In the case of
vancomycin, ﬁtting of the Hill 1 function, a simple sigmoidal function
which is used to describe the cooperative occupation of binding sites on
a molecule by a ligand as a function of ligand concentration [71],
showed binding occurred by a one-step process of moderate aﬃnity
(70 μM) (Hill coeﬃcient = 1.65 ± 0.84) (Fig. 3B). Conversely, teico-
planin was found to bind VanSA by a two-step mechanism (Hill
coeﬃcient = 0.97 ± 0.77; 0.977 ± 0.76) (Fig. 3C). Fitting was per-
formed using a Bi Dose Response function which is a sigmoidal function
monitoring two-step changes induced by exposure to increasing con-
centration of ligand [72]. The proposed diﬀerences in the mechanism of
action for each antibiotic [25] could explain these observed diﬀerences
in mechanism. Alternatively, as teicoplanin is a mixture of compounds
[21] which are present in diﬀerent proportions [20] and display
diﬀerent potencies [20] the observed aﬃnities could result from the
binding of diﬀerent isoforms by VanSA, compared to vancomycin which
is present as a single compound. UV absorption (A) of a material is an
important factor for CD experiments, demonstrated by application of
the Beer-Lambert Law. UV absorption is a complementary spectroscopic
technique which can be used to investigate ligand binding interactions.
Measurements taken at each titration point in the presence of both
GPAs supported CD titration results and the calculated kd (Fig. 4 [79]).
To further investigate the roles of tryptophan (Trp) and tyrosine
(Tyr) in GPA ligand binding, ﬂuorescence spectroscopy and magnetic
synchrotron radiation circular dichroism (MSRCD) techniques were
used. These techniques are powerful tools for the investigation of the
interactions of the aromatic residues, and can provide information
regarding the orientation of the residue of interest (buried or exposed)
within the tertiary structure of the protein. In general, the ﬂuorescence
emission for proteins is assigned to Trp buried in non-polar environ-
ment for λmax < 330 nm and solvent exposed in polar environment for
λmax > 330 nm. The shift of λmax as well as the quenching of
ﬂuorescence emission in the presence of ligands can be used to monitor
binding interactions. Similarly, MSRCD can also be used to probe the
interactions of tryptophan and tyrosine aromatic side-chains with
ligands. A magnetic ﬁeld applied parallel to the direction of light
propagation enables the distinction of overlapping signals not normally
observed using standard CD techniques. MSRCD is most useful when
distinguishing signal contributions from tryptophan and tyrosine as the
diﬀerent transitions of the aromatic rings become distinct. In Fig. 4, the
λmax of 334 nm for VanSA indicative of the tryptophan being more
exposed within the protein tertiary structure was blue shifted to 328 nm
and 329 nm upon addition of vancomycin and teicoplanin (GPAs)
respectively that was attributed with the Trp less exposed (Fig.4) as a
result of antibiotic binding. This was consistent with the MSRCD data
that showed analogous shifts of the peak maxima of VanSA (Fig. 5) in
the presence of GPAs in both tryptophan and tyrosine spectral regions.
The observed red-shifts in the presence of the antibiotics indicated the
residues becoming buried as a result of binding suggesting the aromatic
residues be important components in the antibiotic ligand recognition.
Previous studies identiﬁed a 4-amino-acid motif (DQGW) from the
predicted extracellular binding region of VanSsc (equivalent to the type
B VanS receptor in soil actinomycetes) to which a modiﬁed vancomycin
photoaﬃnity probe bound [51]. Although induction diﬀerences have
been described for the type A and type B receptors [5,27,83], these
results nevertheless suggest an important role for tryptophan in
vancomycin binding.
3.4. Eﬀects of ligand binding on the activity of VanSA
Following structural characterisation of ligand binding by VanSA,
the activity eﬀects of the presence of GPAs vancomycin and teicoplanin,
and peptidoglycan components N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG) were investigated. Results showed signiﬁcant
increases in the activity of VanSA in the presence of GPAs and decreases
in activity in the presence of peptidoglycan components (Fig. 6). It is
hypothesised that in type A resistance systems, vancomycin binding by
VanSA initiates a suppression of phosphatase activity resulting in a net
increase in VanRA phosphorylation [27]. Such activities could account
for the increased phosphorylation of VanSA observed in this study;
however work investigating VanRA phosphorylation in the presence of
GPAs would clarify the mechanism.
The observed diﬀerences in binding (Fig. 3) and phosphorylation
activity (Fig. 6) for VanSA in the presence of teicoplanin may be
reﬂective of the reported potency diﬀerences in vivo of vancomycin and
teicoplanin [84,85]. By reasoning, the observed tighter binding and
increased phosphorylation displayed by VanSA may be a compensatory
mechanism which could result in more eﬀective information relay to
VanRA and activation of resistance gene expression.
4. Conclusion
Here, the characterised binding and activity eﬀects resulting from
ligand binding by VanSA, the sensor regulating the onset of type A
vancomycin resistance in the enterococci, suggest GPAs vancomycin
and teicoplanin themselves and not peptidoglycan components are the
activating ligands for VanSA. Together, this presents a foundation for
understanding the activation mechanism for type A resistance which
has important clinical implications for ways to prevent the development
and spread of resistance, and poses questions regarding the mechanistic
diﬀerences for the activation of type A and type B resistances.
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